Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation

(2011) J. WANG et al.   International Journal of Laboratory Hematology

BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia

(2010) Claire M. Lucas et al.   BRITISH JOURNAL OF HAEMATOLOGY

CIP2A increases self-renewal and is linked to Myc in neural progenitor cells

(2010) Laura Kerosuo et al.   DIFFERENTIATION

PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers

(2010) L. Brault et al.   HAEMATOLOGICA

KIAA1524: A novel MLL translocation partner in acute myeloid leukemia

(2010) Eva A. Coenen et al.   LEUKEMIA RESEARCH

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma

(2010) J Wang et al.   ONCOGENE

The impact of gene profiling in chronic myeloid leukaemia

(2009) Agnes S.M. Yong et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

(2009) I. Cristobal et al.   BLOOD

CIP2A Is Associated with Human Breast Cancer Aggressivity

(2009) C. Come et al.   CLINICAL CANCER RESEARCH

Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells

(2009) Ashley Hamilton et al.   EXPERIMENTAL HEMATOLOGY

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript

(2009) C. M. Lucas et al.   HAEMATOLOGICA

MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer

(2009) Anchit Khanna et al.   JNCI-Journal of the National Cancer Institute

Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

(2009) A K Samanta et al.   ONCOGENE

CIP2A Is Overexpressed in Gastric Cancer and Its Depletion Leads to Impaired Clonogenicity, Senescence, or Differentiation of Tumor Cells

(2008) W. Li et al.   CLINICAL CANCER RESEARCH

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

(2008) Hugues de Lavallade et al.   JOURNAL OF CLINICAL ONCOLOGY

A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials

(2008) C M Lucas et al.   LEUKEMIA